Binnopharm Group rises to the 7th place in the drug sales ranking in the Russian retail market
05.09.2023
According to the AlphaRM analytical agency for July 2023, Binnopharm Group ranks 7th among pharma companies in the Russian pharmaceutical retail market (Sell Out). As of July 2023, Binnopharm Group also ranks 10th among pharmaceutical companies in the market.
Binnopharm Group has the largest sales gain among the TOP-10 corporations in the retail market. In the first seven months of 2023, the company showed a 29% growth in value terms compared to the same period last year (more than 4 billion rubles in absolute terms).
TOP-10 EphMRA groups account for 73% of the total pharmacy sales of drugs by Binnopharm Group in monetary terms in the first seven months of 2023. The largest share (16%) belongs to varicose veins/hemorrhoid medications. The second place (11.75%) goes to systemic antiviral medications. Antimicrobials close the top three with 8.63%.
Rustem Muratov, Chief Executive Officer of Binnopharm Group: «We keep adhering to the chosen strategy of sustainable business development that allows Binnopharm Group to grow above the market regardless of external changes. I would like to emphasize the collaborative work of all the company’s departments. The growth of the company is also facilitated by the upgrade and development of production, expansion of the product portfolio, the effective application of marketing tools, and high expertise in the promotion of medicines».
Anna Ermolaeva, Chief Executive Officer of ALPHA RESEARCH & MARKETING: «Pharmacy sales volume of Binnopharm Group products reached 98.5 million packages in the first seven months of 2023 (+24% compared to the same period in 2022) and totalled 19.4 billion rubles (+29% by July 2023). Having risen three spots compared to YTD’7 2022, Binnopharm Group is now ranking 10th with a share of 2.49%. With the 10th place in January 2023, the company keeps holding its stable positions».
Binnopharm Group has the largest sales gain among the TOP-10 corporations in the retail market. In the first seven months of 2023, the company showed a 29% growth in value terms compared to the same period last year (more than 4 billion rubles in absolute terms).
TOP-10 EphMRA groups account for 73% of the total pharmacy sales of drugs by Binnopharm Group in monetary terms in the first seven months of 2023. The largest share (16%) belongs to varicose veins/hemorrhoid medications. The second place (11.75%) goes to systemic antiviral medications. Antimicrobials close the top three with 8.63%.
Rustem Muratov, Chief Executive Officer of Binnopharm Group: «We keep adhering to the chosen strategy of sustainable business development that allows Binnopharm Group to grow above the market regardless of external changes. I would like to emphasize the collaborative work of all the company’s departments. The growth of the company is also facilitated by the upgrade and development of production, expansion of the product portfolio, the effective application of marketing tools, and high expertise in the promotion of medicines».
Anna Ermolaeva, Chief Executive Officer of ALPHA RESEARCH & MARKETING: «Pharmacy sales volume of Binnopharm Group products reached 98.5 million packages in the first seven months of 2023 (+24% compared to the same period in 2022) and totalled 19.4 billion rubles (+29% by July 2023). Having risen three spots compared to YTD’7 2022, Binnopharm Group is now ranking 10th with a share of 2.49%. With the 10th place in January 2023, the company keeps holding its stable positions».
